Radical External Beam Chemoradiation in Patients With Rectal Cancer: a "Wait-and-see" Approach
Patients with histologically proven adenocarcinoma of the rectum will receive pelvic radiation therapy to a dose of 45Gy in 25 fractions with a tumour boost to a dose of 9Gy in 5 fractions (thus total of 54Gy/30Fx to the primary tumour), combined with radio sensitizing chemotherapy. Patients will then be closely monitored, through endoscopy and imaging, for response to treatment and relapse. Salvage oncologic surgery to be offered if there is failure to achieve complete clinical response or in the event of a loco regional relapse.
Primary Outcome:
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society